Tredje AP fonden Buys 26,991 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Tredje AP fonden raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 200.6% in the fourth quarter, Holdings Channel reports. The firm owned 40,447 shares of the biopharmaceutical company’s stock after acquiring an additional 26,991 shares during the quarter. Tredje AP fonden’s holdings in Alnylam Pharmaceuticals were worth $16,084,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $36,000. Finally, Newbridge Financial Services Group Inc. bought a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $39,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $294.30 on Wednesday. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $284.19 and a 12 month high of $495.55. The stock has a 50 day moving average of $312.56 and a 200-day moving average of $362.08. The company has a market capitalization of $39.29 billion, a P/E ratio of 80.41 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the company posted ($0.44) EPS. The firm’s revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Citigroup assumed coverage on Alnylam Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $380.00 price target for the company. Finally, Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the transaction, the executive vice president directly owned 21,860 shares in the company, valued at approximately $6,989,297.80. The trade was a 7.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 21,255 shares of company stock worth $6,930,337 in the last three months. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.